title: [Visceral leishmaniasis related to infliximab administration].
authors.forename: Verónica
authors.initials: V
authors.lastname: Romaní-Costa
authors.forename: Carlos
authors.initials: C
authors.lastname: Sánchez
authors.forename: Francesca
authors.initials: F
authors.lastname: Moyá
authors.forename: Cristina
authors.initials: C
authors.lastname: Estany
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D048909:Diabetes Complications; D004283:Dog Diseases / Q000469:parasitology; D004285:Dogs; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D007898:Leishmaniasis, Visceral / Q000209:etiology* / Q000635:transmission / Q000662:veterinary; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000209:etiology* / Q000469:parasitology / Q000635:transmission
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000069285:Infliximab